• In late June 2026, Relay Therapeutics, Inc. was added to multiple Russell growth benchmarks, including the Russell 3000 Growth, Russell 2000 Growth, Russell 2500 Growth, Russell 3000E Growth, and the Russell Small Cap Comp Growth indexes.
• This broad-based inclusion across several influential growth indexes can increase Relay Therapeutics’ visibility among institutional investors and index-tracking funds, potentially reshaping how the market views its role within the small- and mid-cap biotech universe.
• Next, we’ll examine how Relay Therapeutics’ entry into several Russell growth indexes may influence its investment narrative and investor perception.

The latest GPUs need a type of rare earth metal called Terbium and there are only 30 companies in the world exploring or producing it. Find the list for free.

What Is Relay Therapeutics' Investment Narrative?

To own Relay Therapeutics, you have to believe that its precision oncology platform, anchored by zovegalisib’s transition toward Phase 3, can eventually justify ongoing heavy losses and a premium valuation. The recent addition to several Russell growth indexes fits cleanly into that story: it could broaden the shareholder base and add trading liquidity, but it does not fundamentally change the near term catalysts, which still center on clinical readouts, regulatory interactions and execution of the Elevar partnership. Likewise, the biggest risks remain intact, including Relay’s reliance on a small number of lead programs, consistent cash burn funded through equity issuance and a price-to-book multiple above biotech peers. The index news may reinforce investor attention, yet it does little to soften those core business uncertainties.

However, one risk investors should not overlook relates to future dilution and funding needs. In light of our recent valuation report, it seems possible that Relay Therapeutics is trading beyond its estimated value.

Exploring Other Perspectives

The Simply Wall St Community’s single fair value estimate of US$24,818.18 shows how concentrated individual views can be. Against this, Relay’s premium valuation and continued losses invite you to weigh clinical progress against financing and execution risks.

Explore another fair value estimate on Relay Therapeutics - why the stock might be worth as much as 33% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Relay Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Relay Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Relay Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.